April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
3 citations
,
March 2023 in “JAAD case reports” Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
March 2026 in “Tropical Journal of Natural Product Research” Albizia saponaria bark extract may help treat hair loss.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
May 2024 in “Archives of dermatological research” Enz_MoriL from mulberry leaves helps hair growth by affecting specific cell pathways.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
July 2023 in “Dermatology and therapy” People with alopecia areata may have a higher risk of blood clots.
October 2021 in “Journal of the European Academy of Dermatology and Venereology” There have been major advances in diagnosing and treating hair loss over the last 30 years, with new drugs and improved hair transplant techniques.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
82 citations
,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
9 citations
,
July 2022 in “EMBO molecular medicine” Blocking certain immune signals can reduce skin damage from radiation therapy.
3 citations
,
September 2025 in “Frontiers in Immunology” JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
April 2026 in “Antibodies” The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.
March 2026 in “Biomedicines” New treatments like biologics and JAK inhibitors show promise for severe scalp inflammation when traditional methods fail.
April 2025 in “Acta Dermato Venereologica” Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.